Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Average Rating of “Moderate Buy” by Analysts

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have earned a consensus rating of “Moderate Buy” from the twenty-three analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, seven have issued a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $1,015.38.

Several research firms have recently commented on REGN. Leerink Partnrs downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Barclays decreased their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Cantor Fitzgerald restated a “neutral” rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. BMO Capital Markets decreased their target price on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Finally, JPMorgan Chase & Co. dropped their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $681.58 on Monday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The stock has a market cap of $74.90 billion, a PE ratio of 16.87, a PEG ratio of 1.60 and a beta of 0.10. The company’s fifty day moving average is $741.54 and its 200 day moving average is $952.59. Regeneron Pharmaceuticals has a 52 week low of $666.25 and a 52 week high of $1,211.20.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in REGN. Ashton Thomas Private Wealth LLC bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $39,000. LPL Financial LLC raised its stake in Regeneron Pharmaceuticals by 16.4% during the second quarter. LPL Financial LLC now owns 47,242 shares of the biopharmaceutical company’s stock valued at $49,653,000 after buying an additional 6,660 shares during the last quarter. BOKF NA boosted its holdings in Regeneron Pharmaceuticals by 6.5% in the second quarter. BOKF NA now owns 1,965 shares of the biopharmaceutical company’s stock worth $2,065,000 after acquiring an additional 120 shares in the last quarter. HBK Sorce Advisory LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth $204,000. Finally, CoreCap Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at $329,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.